Aeglea BioTherapeutics, Inc. (AGLE) Misses Q3 EPS by 842c

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) reported Q3 EPS of ($9.34), $8.42 worse than the analyst estimate of ($0.92).

For earnings history and earnings-related data on Aeglea BioTherapeutics, Inc. (AGLE) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• X Financial (XYF) Tops Q2 EPS by 438c
• Howmet Aerospace Inc. (HWM) PT Raised to $328 at Bernstein SocGen Group